CEO Comments

Read more:


Archive per year

CEO Comment Q2 2022

ORDER FROM INSULIN MANUFACTURERS LAYS FOUNDATION FOR CHARGING FORWARD During the quarter, we launched our product line NLAB Saga® for preparative chromatography, after finalizing large volumes of the first products at the large-scale production facility. NLAB Saga® has initially been very well received by customers, which was shown by an order from one of the world’s largest insulin manufacturers in August, for evaluation of the product at production scale. If the products meet the customer’s

Read more »

CEO Comment Q1 2022

A NEW CHAPTER BEGINS  On March 29, 2022, a new chapter in Nanologica’s history began – as listed on a regulated market. By listing the share on Nasdaq Stockholm Main Market, we get an increased exposure and a better opportunity to attract institutional and international owners.  At the same time, we are now launching our products for preparative chromatography. The big event of the quarter was the change of lists to Nasdaq Stockholm Main Market,

Read more »

CEO Comment Q4 2021

AN EXCITING TIME AHEAD During the year, major changes have been made in the company’s two business areas; in Chromatography, Nanologica now focuses mainly on preparative chromatography, and in Drug Development the strategy has been refined to focus on inhaled drugs and respiratory diseases. This has been done to create the best possible growth conditions and value development going forward, for each business area as well as for the company as a whole. In line

Read more »

CEO comment third quarter 2021

FOCUS ON PRODUCTION! Net sales for the quarter increased marginally to TSEK 2,119, most of which again is derived from our partner project with Vicore Pharma. The quarter’s increased operating loss compared to the previous year is according to plan and is mainly due to the expansion phase in which the company is currently in. To take the next step in our growth, we are now fully focused on completing large-scale production capacity, which is

Read more »

CEO Comment Second Quarter 2021

LARGE-SCALE PRODUCTION AND TOXICITY STUDIES Production of the company’s silica for preparative chromatography in large scale proceeds according to plan. Commercial material is expected to be delivered at the end of the year, after which the company can start delivering on customer agreements. At the same time, we continue to strengthen our platform in inhalation and respiratory diseases with a comprehensive tox program and increased resources for development and commercialization. Net sales for the second

Read more »

CEO Comment First Quarter 2021

IMPORTANT MILESTONES ACHIEVED IN BOTH BUSINESS AREAS Successful upscaling of the production of silica to ton scale advances Nanologica’s position in the preparative chromatography field. At the same time, the company’s platform for inhalation advances through a toxicology program, with eyes set on clinical studies. Sales for the first quarter amounted to TSEK 5,622, where the majority is derived from our partner project with Vicore Pharma. This is our strongest first quarter yet and we

Read more »